Overview of a Phase II clinical trial of isatuximab

Joseph R Mikhael, MD from the Mayo Clinic, Scottsdale, AZ provides an overview of a Phase II clinical trial of isatuximab (SAR650984) for the treatment of relapsed/refractory multiple myeloma (MM). Isatuximab is an anti-CD38 monoclonal antibody, that is very well tolerated by MM patients, with a response rate of 20-29% based on different cohorts. This drug is now being taken into a larger Phase II trial with over 100 patients taking one single dose of isatuximab.
Recorded at the American Society of Hematology (ASH) 2015 Annual Meeting, held in Orlando, FL.

To see more videos go to http://www.vjhemonc.com/

Facebook: https://www.facebook.com/vjhemonc
Twitter: https://twitter.com/VJHemOnc